- Global Pharma News & Resources

Ionis Pharmaceuticals to hold cardio-renal franchise webcast

CARLSBAD, Calif., Aug. 26, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, September 2nd at 10:00 a.m. Eastern Time to review its cardio-renal franchise. The approximately 90-minute webcast will include presentations from Brett P. Monia, Ph.D., chief executive officer; Sam Tsimikas, M.D., senior vice president, global cardiovascular development; Sanjay Bhanot, M.D., Ph.D., chief medical officer; and Richard Geary, Ph.D., executive vice president, development. The agenda for the webcast will be as follows:

Welcome and Introductions

Wade Walke

Ionis – The Leader in RNA-targeted Drug Discovery and Development

Brett Monia

Ionis – Leading the Way in Targeting Cardiovascular and Renal Diseases

Sam Tsimikas

Medicines Targeting Triglyceride-driven Diseases

ο    Akcea-APOCIII-LRx

ο   Vupanorsen (AKCEA-ANGPTL3-LRx)

Sam Tsimikas

Thrombosis: IONIS-FXI-LRx

Sanjay Bhanot

Apolipoprotein(a): AKCEA-APO(a)-LRx

Sam Tsimikas

Transthyretin Amyloid Cardiomyopathy: AKCEA-TTR-LRx

Richard Geary

Treatment Resistant Hypertension: IONIS-AGT-LRx

Richard Geary


Brett Monia



Interested parties may access the webcast at A webcast replay will be available for a limited time at the same address.

About Ionis Pharmaceuticals
As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 novel medicines designed to potentially treat a broad range of disease, including neurological, cardio-renal, metabolic, infectious, and pulmonary diseases.

To learn more about Ionis visit and follow us on twitter @ionispharma.

View original content to download multimedia:

SOURCE Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals to hold cardio-renal franchise webcast

Editor Details

Last Updated: 26-Aug-2020